Perha Pharmaceuticals
Sarah Letemplier has a diverse work experience spanning several industries and roles. Sarah currently serves as the Chief Executive Officer at Perha Pharmaceuticals, a position they have held since April 2023. Prior to this, they were the Chief Financial Officer at Perha Pharmaceuticals from July 2019 to March 2023.
Before joining Perha Pharmaceuticals, Sarah worked as the Chief Financial Officer at ManRos Therapeutics from January 2017 to March 2023. Sarah has also gained experience in investment banking as an Investment Banking Autumn Analyst at Credit Suisse from September 2016 to December 2016.
Sarah's earlier roles include serving as a Junior Investment Manager at Investisseurs & Partenaires - I&P from May 2016 to August 2016, Treasurer at Transaction EM Lyon from January 2015 to December 2015, Risk and Control Analyst at Agence France Locale from June 2015 to September 2015, Assistant Manager at La Bastide de France from June 2014 to December 2014, and Consultant of the Financial Director at Mann & Noble from July 2014 to September 2014.
Overall, Sarah Letemplier's work experience demonstrates their expertise in finance and management roles in various industries.
Sarah Letemplier obtained their high school diploma in Science with honors from Lycée Emile Zola from 2008 to 2011. Sarah then pursued a classe préparatoire économique voie scientifique at Lycée Saint-Louis, Paris VI from 2011 to 2013. Sarah continued their education at Université Lumière Lyon 2 from 2015 to 2016, where they earned a Bachelor's degree in Business Law. Finally, they attended emlyon business school from 2013 to 2017, completing a Master of Science (MSc) in Management.
This person is not in any teams
Perha Pharmaceuticals
Perha Pharmaceuticals is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors and developing them up to proof-of-concept in man. Perha Pharma focuses its research on two main diseases: cognitive disorders associated with Down syndrome (DS) and Alzheimer’s disease (AD), and hearing loss (HL) induced by ototoxic products. The first proof-of-concept in man should be achieved in both pathologies through niche indications: cognitive deficits in DS and hearing loss induced by cis-platin or aminoglycoside antibiotics. Perha Pharma was co-founded in April 2019 by Dr Laurent MEIJER, Chairman & CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de LAVENNE, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr. Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Perha Pharma focuses its research & development on two main programs: - Correction of cognitive deficits associated with Down syndrome: Trisomy 21 and Alzheimer's disease share a common therapeutic target involved in cognitive disorders, the DYRK1A protein kinase. The pharmacological inhibitors of this kinase optimized by Perha Pharma are derived from Leucettamine B, extracted from the Leucetta microraphis marine sponge. These molecules correct cognitive impairments observed in three mouse models of DS and three rodent models of AD. Leucettinib 21, our preclinical drug candidate, has been selected among over 500 synthesized Leucettinibs following a stringent multi-parameter go / no go decision tree. Perha Pharma is now preparing for regulatory preclinical studies. -Prevention of hearing loss induced by ototoxic drugs or noise: Perha Pharma-optimized molecules prevent hair cell apoptosis of the inner ear in cell models exposed to cisplatin. Perha Pharma is working at a proof-of-concept using rodents exposed to cisplatin or acoustic trauma.